CovidResearchTrials by Shray Alag


CovidResearchTrials Covid 19 Research using Clinical Trials (Home Page)


EnzalutamideWiki

Developed by Shray Alag
Clinical Trial MeSH HPO Drug Gene SNP Protein Mutation


Correlated Drug Terms (2)


Name (Synonyms) Correlation
drug2604 Upadacitinib (ABT-494) Wiki 1.00
drug1822 Placebo Wiki 0.06

Correlated MeSH Terms (3)


Name (Synonyms) Correlation
D014456 Ulcer NIH 0.41
D003092 Colitis NIH 0.41
D003093 Colitis, Ulcerative NIH 0.41

Correlated HPO Terms (2)


Name (Synonyms) Correlation
HP:0002583 Colitis HPO 0.41
HP:0100279 Ulcerative colitis HPO 0.41

There is one clinical trial.

Clinical Trials


1 COVID_ENZA Trial: Randomized Open Label Phase II Study to Evaluate the Efficacy of Enzalutamide in High Risk Male Outpatients With COVID-1

High risk outpatient adult males with a confirmed SARS-CoV-2 infection will be included in the study. Patients will be randomized to receive Enzalutamide with standard of care (SOC) or SOC alone. Enzalutamide will be administered daily p.o. from Day 1 to Day 28 or until confirmed negativization of Nasopharyngeal swap (NPS) Polymerase chain reaction (PCR) (2 consecutive negative samples), whichever occurs first.

NCT04456049 COVID-19 Infection Drug: Enzalutamide

Primary Outcomes

Description: efficacy of Enzalutamide in decreasing the nasopharyngeal swap SARS-CoV-2 viral load until negativization

Measure: Efficacy of Enzalutamide

Time: 28 days

Secondary Outcomes

Description: Efficacy of Enzalutamide in controlling disease progression of SARS-CoV-2 viral load

Measure: Disease progression

Time: 28 days

Description: Evaluation of Enzalutamide tolerability in terms of incidence and severity grade of side effects

Measure: Tollerability of Enzalutamide

Time: 28 days


No related HPO nodes (Using clinical trials)